Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer
S Deva, M Jameson - Cochrane Database of Systematic …, 2012 - cochranelibrary.com
Background Anecdotal reports of tumour regression with histamine type 2 receptor
antagonists (H 2 RAs) have lead to a series of trials with this class of drug as adjuvant …
antagonists (H 2 RAs) have lead to a series of trials with this class of drug as adjuvant …
[HTML][HTML] Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
J Desai, S Deva, JS Lee, CC Lin, CJ Yen… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1)
axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used …
axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used …
Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment-naïve head and neck squamous cell carcinoma: results from a multicenter, phase II …
EEW Cohen, L Nabell, DJ Wong, T Day, GA Daniels… - Clinical cancer …, 2022 - AACR
Purpose: To determine whether SD-101, a Toll-like receptor 9 agonist, potentiates the
antitumor activity of anti-PD-1 antibodies in patients with anti-PD-1/PD-L1 naïve …
antitumor activity of anti-PD-1 antibodies in patients with anti-PD-1/PD-L1 naïve …
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial
RJ Broom, V Hinder, K Sharples, J Proctor… - Clinical genitourinary …, 2015 - Elsevier
Background Bone metastases from renal cell carcinoma (RCC) are a major cause of
morbidity. Post hoc analysis has suggested that bone turnover markers can identify patients …
morbidity. Post hoc analysis has suggested that bone turnover markers can identify patients …
Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic …
EEW Cohen, L Nabell, DJL Wong, TA Day, GA Daniels… - 2019 - ascopubs.org
6039 Background: SD-101, a synthetic CpG-ODN agonist of TLR9, stimulates dendritic cells
to release IFN-alpha and mature into antigen presenting cells-activating T cell anti-tumor …
to release IFN-alpha and mature into antigen presenting cells-activating T cell anti-tumor …
[HTML][HTML] The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction …
Z Lu, S Yang, X Luo, Y Shi, JS Lee, S Deva, T Liu… - Gastric Cancer, 2022 - Springer
Abstract Background In solid tumor Phase 1/2 trials (NCT02407990; NCT04068519),
tislelizumab demonstrated clinical benefit, including in advanced gastroesophageal …
tislelizumab demonstrated clinical benefit, including in advanced gastroesophageal …
Response to BRAF-targeted therapy is enhanced by cotargeting VEGFRs or WNT/β-catenin signaling in BRAF-mutant colorectal cancer models
KB Tran, S Kolekar, Q Wang, JH Shih… - Molecular Cancer …, 2022 - AACR
The fact that 10% of colorectal cancer tumors harbor BRAF V600E mutations suggested
targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single …
targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single …
A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
S Deva, JS Lee, CC Lin, CJ Yen… - Annals of …, 2018 - annalsofoncology.org
Background: Tislelizumab, a humanized IgG4 monoclonal Ab with high affinity and
specificity for PD-1, was engineered to minimize binding to FcγR on macrophages, thus …
specificity for PD-1, was engineered to minimize binding to FcγR on macrophages, thus …
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study
CGCA Jackson, T Hung, E Segelov… - British Journal of …, 2021 - Wiley Online Library
Aims Paclitaxel is a widely used anti‐neoplastic agent but has low oral bioavailability due to
gut extrusion by P‐glycoprotein (P‐gp). Oral paclitaxel could be more convenient, less …
gut extrusion by P‐glycoprotein (P‐gp). Oral paclitaxel could be more convenient, less …
Cardiac troponin I and T in checkpoint inhibitor–associated myositis and myocarditis
E Ang, A Mweempwa, C Heron, Y Ahn… - Journal of …, 2021 - journals.lww.com
Checkpoint inhibitor–associated myocarditis (ir-myocarditis) and myositis (ir-myositis) may
occur concurrently among patients on checkpoint inhibitor immunotherapy. While cardiac …
occur concurrently among patients on checkpoint inhibitor immunotherapy. While cardiac …